Karyopharm Therapeutics | KPTI - Дебиторская задолженность





Дебиторская задолженность Изменить Дата
AbbVie USD 12.77B 132M 2025-09
Abbott USD 10.4B 166M 2025-09
Amgen USD 9.57B 1.08B 2025-12
AstraZeneca USD 19.05B 1.49B 2025-12
BioCryst Pharmaceuticals USD 106.82M 15.49M 2025-12
Bristol-Myers Squibb USD 14.62B 485M 2025-09
Eli Lilly USD 19.46B 2.25B 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
GlaxoSmithKline GBP 7.76B 545M 2025-12
Incyte USD 1.02B 128.52M 2025-12
J&J USD 17.61B 235M 2025-09
Karyopharm Therapeutics USD 31.78M 6.82M 2024-09
MacroGenics USD 13.37M 55.86M 2025-12
Merck USD 12.12B 596M 2025-09
Nektar Therapeutics USD 0 2.9M 2024-09
Novartis USD 12.29B 3.3B 2025-12
Novartis USD 12.29B 3.3B 2025-12
Pfizer USD 18.12B 2.02B 2025-09
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sangamo BioSciences USD 581K 110K 2024-06
Takeda JPY 757.92B 55.68B 2025-12
Tectonic Therapeutic USD 0 270K 2023-12
TG Therapeutics USD 265.38M 33.86M 2025-09
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Xencor USD 29.3M 7.49M 2025-12